Biomarker to measure drug efficacy in enteropathic disease
View Patent ↗The response of a patient with an enteropathic disease to therapy, particularly a candidate therapy in a clinical trial setting, is assessed by detecting the ability of the patient to metabolize an orally administered CYP3A substrate. The CYP3A metabolism may be monitored in a variety of ways. Conveniently, the appearance of a metabolite of the CYP3A substrate is detected in a patient sample over a period of time following oral administration, e.g. in urine, plasma, breath, saliva, etc. The CYP3A substrate is optionally labeled, e.g. with an isotopic, fluorescent, etc. label.
1. A non-invasive method for assessing the efficacy of a clinical regimen in the treatment of an individual with an intolerance to gluten, the method comprising:
identifying an individual as having an intolerance to gluten undergoing treatment with a clinical regimen of interest;
administering an oral dose of a CYP3A substrate to the individual,
quantitating a post dose concentration of the CYP3A substrate and/or its metabolite(s) in at least one sample from the individual, selected from the group consisting of blood, saliva, urine and breath;
assessing efficacy of the regimen, wherein an efficacious regimen protects from gluten-induced enteropathy that results in decreased enteric metabolism of the CYP3A substrate relative to a gluten-tolerant control sample, to generate an analysis of efficacy; and
providing the analysis of the efficacy of the clinical regimen, wherein the extent of metabolism of the CYP3A substrate to its metabolite, indicated by said post-dose concentration, is a non-invasive surrogate for the efficacy of the clinical regimen in protecting the individual from gluten-induced enteropathy.
2. The method of claim 1 , wherein the individual is a human.
3. The method of claim 1 , wherein the CYP3A substrate is midazolam.
4. The method of claim 3 , wherein the presence of midazolam, 1′-hydroxymidazolam, and/or 4-hydroxymidozalam is quantitated in a sample from the individual.
5. The method of claim 1 , where the CYP3A substrate is simvastatin.
6. The method of claim 1 , wherein the steps of administering a CYP3A substrate and quantitating the presence of the CYP3A substrate and/or its metabolite(s) in at least one sample from the individual are performed at two or more time points, where the disease status of the individual is expected to differ between the time points as the result of administering the clinical regimen to the individual.
7. The method of claim 1 , wherein the individual is one of a group of individuals in a clinical trial.
8. The method of claim 7 , wherein the clinical trial is a crossover trial.
9. The method of claim 7 , wherein the clinical trial is a double blinded parallel trial.
10. The method of claim 1 , wherein the efficacy of treatment for an individual with an intolerance to gluten is assessed by determining the decrease in enteric CYP3A metabolism of the CYP3A substrate, wherein an effective treatment protects from gluten-induced enteropathy and an area under a concentration-time curve (AUC) for the CYP3A substrate will remain unchanged after gluten challenge; and for an ineffective treatment the AUC for the CYP3A substrate will increase after gluten Challenge.
11. The method of claim 1 , wherein the efficacy of treatment for an individual with an intolerance to gluten is assessed by determining the decrease in enteric CYP3A metabolism of the CYP3A substrate, wherein an effective treatment protects from gluten-induced enteropathy and a maximum concentration (C max ) for the CYP3A substrate will remain unchanged after gluten challenge; and for an ineffective treatment the C max for the CYP3A substrate will increase after gluten challenge.
12. The method of claim 1 , wherein the efficacy of treatment for an individual with an intolerance to gluten is assessed by determining the decrease in enteric CYP3A metabolism of simvastatin, wherein an effective treatment protects from gluten-induced enteropathy and a maximum concentration (C max ) for simvastatin will remain unchanged after gluten challenge; and for an ineffective treatment the C max for simvastatin will increase after gluten challenge.
13. A non-invasive method for assessing the efficacy of a clinical regimen in the treatment of an individual with an intolerance to gluten, the method comprising:
identifying an individual as having an intolerance to gluten undergoing treatment with a clinical regimen of interest;
administering an oral dose of simvastatin to the individual;
measuring serum concentration from 30 minutes to 3 hours post-dose of simvastatin, 3′-hydroxy simvastatin, 6′-exomethylene simvastatin, 3′,5′-dihydrodiol simvastatin, and/or simvastatin (β)-hydroxy acid in at least one sample from the individual;
assessing efficacy of the regimen, wherein an efficacious regimen protects from gluten-induced enteropathy that results in decreased enteric metabolism of the simvastatin relative to a gluten-tolerant control sample, to generate an analysis of efficacy; and
providing the analysis of the efficacy of the clinical regimen, wherein the extent of simvastatin metabolism, indicated by said post-dose concentration, is a non-invasive surrogate for the efficacy of the clinical regimen in protecting the individual from gluten-induced enteropathy.
14. The method of claim 13 , wherein the efficacy of treatment for an individual with an intolerance to gluten is assessed by determining the decrease in enteric CYP3A metabolism of the simvastatin, wherein an effective treatment protects from gluten-induced enteropathy and an area under a concentration-time curve (AUC) for simvastatin will remain unchanged after gluten challenge; and for an ineffective treatment the AUC for simvastatin will increase after gluten challenge.
15. A non-invasive method for clinical management of an individual with an intolerance to gluten, the method comprising:
identifying an individual as having an intolerance to gluten undergoing treatment with a current clinical regimen of interest;
administering an oral dose of simvastatin to the individual;
measuring serum concentration from 30 minutes to 3 hours post-dose of simvastatin, 3′-hydroxy simvastatin, 6′-exomethylene simvastatin, 3′,5′-dihydrodiol simvastatin, and/or simvastatin (β)hydroxy acid in at least one sample from the individual;
assessing efficacy of the current regimen, wherein an efficacious regimen protects from gluten-induced enteropathy that results in decreased enteric metabolism of the simvastatin relative to a gluten-tolerant control sample; and
providing a clinical regimen to the individual in accordance with an analysis of the efficacy of the current clinical regimen wherein the extent of simvastatin metabolism, indicated by said post-dose concentration, is a non-invasive surrogate for the efficacy of the current clinical regimen in protecting the individual from gluten-induced enteropathy.